Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is at 88; compared to its 52-week range of 79 to 399.